@article{0fd5b3dce4624413b3622a5d264ff910,
title = "Clinical characteristics and outcomes of duodenal-type follicular lymphoma",
author = "Ryohei Abe and Takehiko Mori and Tomohiko Tanigawa and Yuya Koda and Naoki Hosoe and Masatoshi Sakurai and Taku Kikuchi and Jun Kato and Takayuki Shimizu and Haruhiko Ogata and Takanori Kanai and Aya Sasaki and Kaori Kameyama and Shinichiro Okamoto",
note = "Funding Information: TM received research funding from MSD, Novartis Pharma, LSI Medience, Medical \& Biological Laboratories, and Asahi Kasei Corporation, and personal fees from Pfizer Inc., MSD, Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma, Kyowa Kirin, Chugai Pharmaceutical, Shionogi \& Co., Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai, and Astellas Pharma; TK received personal fees from Chugai Pharmaceutical, Eisai, Kyowa Kirin, Janssen Pharma, Takeda Pharmaceutical, and Bristol-Myers Squibb; JK received personal fees from Astellas Pharma, Otsuka Pharmaceutical, Janssen Pharma, Pfizer, Takeda Pharmaceutical, and JCR Pharmaceuticals; TS received personal fees from Janssen Pharma, Kyowa Kirin, Takeda Pharmaceutical, Celgene, Ono Pharmaceutical, and Eisai; SO received research funding from Chugai Pharmaceutical, Sumitomo Dainippon Pharma, Pfizer, Teijin Pharma, Novartis Pharma, Bristol-Myers Squibb, Mochida Pharmaceutical, JCR Pharmaceuticals, Toyama Chemical, Takeda Pharmaceutical, Daiichi Sankyo, Shionogi \& Co., Sanofi, Kyowa Kirin, Ono Pharmaceutical, Otsuka Pharmaceutical, Eisai, Asahi Kasei Corporation, and Japan Blood Products Organization, and personal fees from Chugai Pharmaceutical, Eisai, Kyowa Kirin, Janssen Pharma, and Takeda Pharmaceutical.",
year = "2020",
doi = "10.1080/10428194.2020.1795162",
language = "English",
pages = "3266--3268",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
}
SDG 3 すべての人に健康と福祉を